Effect of Ritonavir-boosting on Atazanavir Discontinuation due to Jaundice in HIV-infected Koreans / 감염과화학요법
Infection and Chemotherapy
; : 175-179, 2012.
Article
em Ko
| WPRIM
| ID: wpr-216369
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND: Data regarding differences of intolerance between a ritonavir-unboosted and a ritonavir-boosted atazanavir regimen in HIV-infected Koreans is limited. MATERIALS AND METHODS: A review was conducted of the incidence of severe hyperbilirubinemia (serum total bilirubin >3.1 mg/dL) and discontinuation of atazanavir in HIV-infected patients who had received an atazanavir-containing regimen at Seoul National University Hospital from 2005 to 2009. Patients with active liver disease were excluded from the study. RESULTS: Of a total of 335 patients receiving an atazanavir-containing regimen, 145 (43.3%) received treatment with a ritonavir-boosted regimen. The cumulative incidence of severe hyperbilirubinemia at three months was 40.5% in patients receiving a ritonavir-boosted atazanavir regimen and 21.4% in patients receiving an un-boosted atazanavir regimen (P<0.001). The cumulative incidence of severe hyperbilirubinemia at 12 months was 58.5% in patients receiving a ritonavir-boosted regimen and 41.3% in those receiving an un-boosted regimen (P=0.008). The proportion of drug discontinuation due to jaundice during the 12-month period was 11.7% in patients receiving a ritonavir-boosted regimen and 5.3% in those receiving an un-boosted regimen (P=0.035). CONCLUSIONS: Occurrence of severe hyperbilirubinemia and discontinuation of atazanavir due to jaundice was significantly more common in HIV-infected Koreans who received a ritonavir-boosted atazanavir regimen than in those who received a ritonavir-un-boosted atazanavir regimen.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Oligopeptídeos
/
Piridinas
/
Bilirrubina
/
Incidência
/
HIV
/
Ritonavir
/
Sulfato de Atazanavir
/
Hiperbilirrubinemia
/
Icterícia
/
Hepatopatias
Tipo de estudo:
Incidence_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
Ko
Revista:
Infection and Chemotherapy
Ano de publicação:
2012
Tipo de documento:
Article